Credit Suisse Ag Vaxart, Inc. Transaction History

Credit Suisse Ag

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.75 - $2.24 $68,049 - $203,239	-90,732 Reduced 93.65%	6,157 $5,000
Q3 2022 Nov 10, 2022	BUY	$2.09 - $4.5 $1,435 - $3,091	687 Added 0.71%	96,889 $211,000
Q2 2022 Aug 12, 2022	BUY	$2.7 - $5.28 $2,108 - $4,123	781 Added 0.82%	96,202 $337,000
Q1 2022 May 16, 2022	BUY	$4.29 - $6.64 $26,610 - $41,187	6,203 Added 6.95%	95,421 $481,000
Q4 2021 Feb 14, 2022	SELL	$5.77 - $7.96 $24,539 - $33,853	-4,253 Reduced 4.55%	89,218 $559,000
Q3 2021 Nov 12, 2021	SELL	$6.67 - $9.8 $168,043 - $246,901	-25,194 Reduced 21.23%	93,471 $744,000
Q2 2021 Aug 16, 2021	SELL	$5.06 - $10.78 $29,044 - $61,877	-5,740 Reduced 4.61%	118,665 $889,000
Q1 2021 May 14, 2021	SELL	$5.64 - $23.33 $1.12 Million - $4.65 Million	-199,303 Reduced 61.57%	124,405 $753,000
Q4 2020 Feb 12, 2021	BUY	$3.5 - $7.98 $1.07 Million - $2.44 Million	305,331 Added 1661.48%	323,708 $1.85 Million
Q3 2020 Nov 13, 2020	BUY	$4.78 - $16.97 $87,842 - $311,857	18,377 New	18,377 $122,000

110

37.6M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $73.4M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.